At the news
? NEUTRALIMPACT 3/10 DEFA14A filed Apr 16, 2026 at 08:49 ET
Vir Biotechnology filed a definitive proxy statement (DEFA14A) following the recent departure of its Chief Medical Officer, Mark Eisner. The filing is routine and does not indicate any material changes or shareholder disputes.
- Filed a DEFA14A proxy statement
- Follows the recent departure of Chief Medical Officer Mark Eisner
- No activist campaign or shareholder dispute mentioned
- Filing is routine and procedural
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access